# A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

> **NCT05414175** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 38 (actual)

## Conditions studied

- Cardiomyopathy, Hypertrophic Obstructive

## Interventions

- **DRUG:** Mavacamten

## Key facts

- **NCT ID:** NCT05414175
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-19
- **Primary completion:** 2023-11-27
- **Final completion:** 2025-12-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05414175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05414175, "A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05414175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*